文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

主动脉瓣狭窄合并心脏淀粉样变的患病率与结局

Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis.
PubMed 文献 · J Am Coll Cardiol · 2020-11-09

在3个国际中心接受TAVR评估的407例老年重度主动脉瓣狭窄患者中,盲法99mTc-DPD骨闪烁显像发现11.8%为DPD阳性,其中7.9%为2/3级;合并AS-CA者临床表现更差,1年死亡率高于单纯AS(24.5% vs 13.9%,p=0.05),但TAVR后生存与单纯AS无差异(p=0.36)。

要点

  • 重度AS患者中AS-CA并不少见,DPD阳性率11.8%。
  • AS-CA患者功能状态、生物标志物和双心室重构更差。
  • TAVR不应因合并AS-CA而 withheld,其术后生存与单纯AS相当。

核心结论

  • AS-CA在老年AS患者中常见且可临床预测,临床表现更差并有预后更差趋势,但TAVR后生存与单纯AS无差异,故不应拒绝TAVR。

研究设计与样本

  • 多中心前瞻性研究,3个国际中心连续纳入接受TAVR评估的407例患者(年龄83.4±6.5岁,49.8%男性),术前盲法行99mTc-DPD骨闪烁显像,并通过国家注册系统捕获全因死亡。

主要发现

  • DPD阳性48例(11.8%),其中1级3.9%(n=16),2/3级7.9%(n=32);1例1级患者经组织活检诊断为AL型。
  • 2/3级患者功能 capacity、NT-proBNP和/或hs-TnT生物标志物及双心室重构更差。
  • RAISE临床评分预测AS-CA的AUC为0.86(95%CI 0.78-0.94,p<0.001)。
  • 中位随访1.7年,23%患者死亡;AS-CA(1-3级)1年死亡率24.5% vs 单纯AS 13.9%(p=0.05)。
  • TAVR较药物治疗改善生存;AS-CA患者TAVR后生存与单纯AS无差异(p=0.36)。

关键数值与推荐

  • DPD显像Perugini分级:0级阴性,1-3级阳性程度递增;ATTR-CA诊断依据DPD阳性且无克隆性免疫球蛋白,AL-CA依据组织活检。
  • RAISE评分组成:左心室重构(肥厚/舒张功能障碍)、年龄、损伤(hs-TnT)、系统性受累、电学异常(右束支传导阻滞/低电压)。

临床怎么用

  • 对老年重度AS患者可考虑用RAISE评分临床预测合并CA,并行DPD显像确诊。
  • 合并AS-CA不应成为TAVR的禁忌,TAVR可改善生存且术后结局与单纯AS相当。

局限性

  • 样本量407例,中位随访1.7年,事件数有限。
  • 观察性设计,治疗分组非随机。
  • 仅纳入3个国际中心,外推性需验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older patients with severe aortic stenosis (AS) are increasingly identified as having cardiac amyloidosis (CA). It is unknown whether concomitant AS-CA has worse outcomes or results in futility of transcatheter aortic valve replacement (TAVR). OBJECTIVES: This study identified clinical characteristics and outcomes of AS-CA compared with lone AS. METHODS: Patients who were referred for TAVR at 3 international sites underwent blinded research core laboratory 99mtechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) bone scintigraphy (Perugini grade 0: negative; grades 1 to 3: increasingly positive) before intervention. Transthyretin-CA (ATTR) was diagnosed by DPD and absence of a clonal immunoglobulin, and light-chain CA (AL) was diagnosed via tissue biopsy. National registries captured all-cause mortality. RESULTS: A total of 407 patients (age 83.4 ± 6.5 years; 49.8% men) were recruited. DPD was positive in 48 patients (11.8%; grade 1: 3.9% [n = 16]; grade 2/3: 7.9% [n = 32]). AL was diagnosed in 1 patient with grade 1. Patients with grade 2/3 had worse functional capacity, biomarkers (N-terminal pro-brain natriuretic peptide and/or high-sensitivity troponin T), and biventricular remodeling. A clinical score (RAISE) that used left ventricular remodeling (hypertrophy/diastolic dysfunction), age, injury (high-sensitivity troponin T), systemic involvement, and electrical abnormalities (right bundle branch block/low voltages) was developed to predict the presence of AS-CA (area under the curve: 0.86; 95% confidence interval: 0.78 to 0.94; p < 0.001). Decisions by the heart team (DPD-blinded) resulted in TAVR (333 [81.6%]), surgical AVR (10 [2.5%]), or medical management (65 [15.9%]). After a median of 1.7 years, 23% of patients died. One-year mortality was worse in all patients with AS-CA (grade: 1 to 3) than those with lone AS (24.5% vs. 13.9%; p = 0.05). TAVR improved survival versus medical management; AS-CA survival post-TAVR did not differ from lone AS (p = 0.36). CONCLUSIONS: Concomitant pathology of AS-CA is common in older patients with AS and can be predicted clinically. AS-CA has worse clinical presentation and a trend toward worse prognosis, unless treated. Therefore, TAVR should not be withheld in AS-CA.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Nitsche C, Scully PR, Patel KP, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am Coll Cardiol. 2020. PMID: 33181246. doi:10.1016/j.jacc.2020.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。